Expression of the tetraspanin CO-029 is associated with poor prognosis in patients with gastrointestinal cancer. In a pancreatic tumor line, overexpression of the rat homologue, D6.1A, induces lethally disseminated intravascular coagulation, suggesting D6.1A engagement in angiogenesis. D6.1A-overexpressing tumor cells induce the greatest amount of angiogenesis in vivo, and tumor cells as well as exosomes derived thereof strikingly increase endothelial cell branching in vitro. Tumor cell-derived D6.1A stimulates angiogenic factor transcription, which includes increased matrix metalloproteinase and urokinase-type plasminogen activator secretion, pronounced vascular endothelial growth factor expression in fibroblasts, vascular endothelial growth factor receptor expression, and strong D6.1A up-regulation in sprouting endothelium. Thus, D6.1A initiates an angiogenic loop that, probably due to the abundance of D6.1A in tumorderived exosomes, reaches organs distant from the tumor. Most importantly, because of the strong D6.1A up-regulation on sprouting capillaries, angiogenesis could be completely inhibited by a D6.1A-specific antibody, irrespective of whether or not the tumor expresses D6.1A. Tetraspanins have been suggested to be involved in morphogenesis. This is the first report that a tetraspanin, CO-029/D6.1A, promotes tumor growth by its capacity to induce systemic angiogenesis that can effectively, and with high selectivity for sprouting endothelium, be blocked by a D6.1A-specific antibody. (Cancer Res 2006; 66(14): 7083-94) 
Systemic Induction of the Angiogenesis Switch by the Tetraspanin D6.1A/CO-029 Introduction
The term angiogenesis defines the process of new capillary formation from preexisting vasculature that occurs in physiologic as well as pathologic conditions (1) . Tumor cells essentially depend on angiogenesis to grow beyond a threshold size of a few cubic millimeters (2) . Angiogenesis is the result of an intricate balance between proangiogenic and antiangiogenic factors, and the dominance of proangiogenic factors is called the angiogenic switch (3) . One of the main angiogenic switch inducers is hypoxia (4) , whereas the most well-known proangiogenic factor is vascular endothelial growth factor (VEGF; ref. 5) , and matrix metalloproteinases (MMP) are essentially required to create space for sprouting capillaries by degradation of the basal membrane as well as for the liberation of angiogenic factors and for inducing the transcription of angiogenic factors (6, 7) . Recent studies in knockout and transgenic mouse models have provided further evidence that tumor angiogenesis is not only guided by the tumor cell itself, but is also closely tied to the tumor microenvironment (8) .
Tetraspanins are a large family of proteins grouped according to structural relatedness. The key feature of tetraspanins is their potential to associate with each other and with a multitude of molecules from other protein families (9) (10) (11) , the most prominent partners being integrins (12) . The tetraspanin, D6.1A (rat)/CO-029 (human), associates with a3h1 and a6h1 and, after disassembly of hemidesmosomes, with a6h4. It also associates with the tetraspanins, CD9 and CD81, and the immunoglobulin superfamily member, prostaglandin F2a receptor regulatory protein, a type II phosphoinositide-4-kinase, EpCAM, and CD44v4-v7 (13) (14) (15) .
According to their association with different molecules, tetraspanins are assumed to function as adaptors that assemble protein complexes in defined membrane microdomains, called tetraspaninenriched microdomains, that provide a link to specific signaltransducing molecules (16) . This mode of activity might explain why tetraspanins are said to take part in a wide range of diverse functions (9, 11) , such as B and T cell activation, platelet aggregation, migration, proliferation (10, 17, 18) , and tumor cell progression (18, 19) . With respect to the latter, high expression of CD9 (20, 21) and CD82 (22) is mostly associated with a favorable prognosis. CD151, D6.1A, and its human homologue, CO-029, are supposed to exert tumor-promoting activities (23) (24) (25) (26) . A possible mechanistic basis for the prometastatic functions of tetraspanins could be their association with certain integrins and the accompanying increase in cell motility (22, 23) . Furthermore, tetraspanin interactions with platelets and leukocytes were suggested to provide tumor cells with a survival advantage in the hostile environment which they encounter during metastatic spread (27) . CD151 has also been reputed to be involved in cellular morphogenesis, promoting the formation of cord-like structures, considered as a preform of sprouting vessels (28) . Finally, tumor cells can grow in mosaics with endothelial cells, and mosaic growth depends on tetraspanin expression (29) . Taking into account that coagulopathy and thrombosis are frequent complications, particularly in patients with lung and pancreatic cancer (30) , it is important to note that CD9, CD63, and CD151 are expressed by platelets. CD9 and CD63 associate with aIIbh3, which supports activated platelet adhesion to neutrophils and platelet aggregation (31) . In CD151 knockout mice, platelet spreading is impaired, aggregation is reduced, and the bleeding time is prolonged. This is likely due to the absence of an outside-in signal provided by CD151, leading to the activation of aIIbh3 (32) .
D6.1A overexpression on a pancreatic rat adenocarcinoma line is associated with the formation of hemorrhagic ascites (15) and can induce a severe consumption coagulopathy, such that rats become moribund due to disseminated intravascular coagulation rather than the tumor burden (13) . These features prompted us to search for the possible involvement of D6.1A in angiogenesis.
Materials and Methods
Rats and tumors. BDX rats, bred at the animal facilities of the German Cancer Research Centre, were kept under specific pathogen-free conditions, fed sterilized food and water ad libitum. Rats were used for experiments at the age of 6 to 10 weeks. BSp73AS (AS) cells, a pancreatic adenocarcinoma line of the BDX rat strain (33) , were transfected with D6.1A cDNA (AS-D6.1A; ref. 13 ). For intravital microscopy, AS cells were transfected with the enhanced green fluorescent protein (EGFP) cDNAcontaining pEGFP-N1 vector (Becton Dickinson, Heidelberg, Germany). AS-D6.1A cells were transfected with the EGFP cDNA inserted in the pcDNA3.1Hygro vector (Invitrogen, Karlsruhe, Germany). Transfected lines were selected in RPMI 1640, 10% FCS, and 500 Ag/mL of G418. The selection medium for double-transfected lines contained an additional 50 Ag/mL of hygromycin. A BDX fibroblast line, generated by NiSO 4 treatment, and RAEC, a Wistar rat-derived aortic endothelial cell line (Cell-lining, Berlin, Germany) was maintained in RPMI 1640 and 10% FCS. Confluent cultures were trypsinized and split.
Antibodies. The following monoclonal and polyclonal antibodies were used: mouse anti-D6.1A (D6.1; ref. 34) , mouse anti-a6h4 (B5.5; ref. 34) , rabbit anti-CD151 (14) ; anti-CD9 and anti-CD44 (Ox50; European Collection of Animal Cell Cultures); anti-a1, anti-a2, anti-a3, anti-a4, anti-a5, anti-a6, anti-h1, anti-h2, anti-h3, anti-h4, anti-CD31, anti-tumor necrosis factor-a (TNFa), anti-IL4 (BD PharMingen, Heidelberg, Germany); anti-TIMP-1, anti-TIMP-2 (Biozol, Munich, Germany); anti-MMP-2, anti-MMP-9, anti-MMP-13 (Dianova, Hamburg, Germany); anti-VEGFR1, anti-VEGFR2 (Biotrend, Köln, Germany); anti-urokinase-type plasminogen activator receptor (uPAR), anti-uPA (American Diagnostica, Stanford, CT); anti-VEGF, anti-basic fibroblast growth factor (bFGF; R&D, Eschborn, Germany); biotinylated, horseradish peroxidase-and fluorescence dye (FITC, APC, rhodamine, Cy2)-labeled secondary antibodies, and FITC-labeled phalloidin (BD PharMingen and Biotrend).
Flow cytometry. Flow cytometry followed routine procedures using 1 to 3 Â 10 5 cells per sample. Trypsinized cells were allowed to recover for 2 hours at 37jC in RPMI 1640 and 10% FCS. For intracellular staining, cells were fixed and permeabilized in advance. Samples were analyzed with FACSCalibur (Becton Dickinson).
Immunohistochemistry. Cryostat sections (5 Am) of snap-frozen tissue were fixed in chloroform/acetone (1:1, 4 minutes). For intracellular staining, sections were fixed in paraformaldehyde (4%) and were permeabilized (0.1% Triton X-100, 4 minutes, 4jC). Tissues were incubated for 1 hour with the first antibody, washed and exposed to the biotinylated secondary antibodies (30 minutes), and alkaline phosphatase-conjugated avidin-biotin complex (Vector Laboratories, Burlingame, CA) solutions (5-20 minutes). Sections were counterstained with Mayer's hematoxylin. The primary antibody was replaced by normal mouse, rat, or rabbit IgG for negative controls.
For immunofluorescence microscopy, cells were seeded on matrigelcoated cover slides. After 8 hours, cells were fixed in 4% paraformaldehyde (w/v in PBS) and, where indicated, were permeabilized (0.1% Triton X-100, 4 minutes). After washing and blocking (PBS/0.2% gelatin/0.5% bovine serum albumin), cells were incubated with the primary antibody (2-10 Ag/mL, 60 minutes, 4jC). Slides were rinsed and incubated for 60 minutes at 4jC with a fluorochrome-conjugated secondary antibody. Washed cells were incubated with an excess of unlabeled mouse or rabbit IgG to block free binding sites of the secondary antibody. Unlabeled IgG was also added during incubation with the second, dye-labeled antibody (60 minutes, 4jC). Phalloidin-FITC (0.5 Ag/mL) was used for filamentous actin staining (60 minutes, 4jC). After washing thrice in PBS and once in water, slides were mounted in Elvanol. Digitized images were generated using a Leica DMRBE Microscope equipped with a SPOT CCD camera from Diagnostic Instruments, Inc., and Software SPOT2.1.2 (Visitron Systems, Puchheim, Germany).
Preparation of exosomes. AS and AS-D6.1A cells were cultured in RPMI 1640 and 10% exosome-depleted FCS. Exosomes were prepared from supernatant after 2 days of culture by differential centrifugation. Supernatants were centrifuged twice for 10 minutes at 500 Â g, once for 20 minutes at 2,000 Â g, and once for 30 minutes at 10,000 Â g to eliminate cell debris. The purified supernatant was centrifuged for 90 minutes at 100,000 Â g using a SW41 rotor. The pellet was resuspended in PBS and centrifuged again for 90 minutes at 100,000 Â g.
Western blotting. Cell lysates (1% Triton X-100) were resolved on 12% or 15% SDS-PAGE under nonreducing conditions. Proteins were transferred to Hybond enhanced chemiluminescence at 30 V overnight. After blocking (5% fat-free milk powder), immunoblotting was done with the indicated antibodies, followed by horseradish peroxidase-labeled secondary antibodies. Blots were developed with the enhanced chemiluminescence detection system.
Zymography. Cells (10 6 ) were seeded in 24-well plates (35) . After overnight culture, cells were washed and starved in serum-free medium. Conditioned medium was collected after 24 hours and was centrifuged (15 minutes, 15,000 Â g ) to remove cell debris. Aliquots were incubated with Laemmli buffer (15 minutes, 37jC) and separated in a 10% acrylamide gel containing 1 mg/mL of gelatin. The gel was washed for 30 minutes each in 2.5% Triton X-100, 2.5% Triton X-100/50 mmol/L Tris (pH 7.5), and 2.5% Triton X-100/50 mmol/L Tris (pH 7.5), 5 mmol/L CaCl 2 , 1 Amol/L ZnCl 2 . Gels were incubated (24-48 hours, 37jC) in 50 mmol/L Tris (pH 7.5), 5 mmol/L CaCl 2 , 1 Amol/L ZnCl 2 , and stained with Coomassie blue.
Matrigel assay. Tumor cells (10 5 ) were seeded on matrigel-coated 24-well plates. Where indicated, antibodies (10 Ag/mL) were added to the culture medium. Cable formation was evaluated after 7 and 48 hours and was documented by light microscopy.
In vitro angiogenesis. The mesentery was collected from 6-week-old rats and 1 cm 2 pieces were placed in six-well plates in RPMI 1640 and 10% FCS. Tumor cells (5 Â 10 5 ), supernatant of confluent tumor cell cultures (1:1 diluted with fresh medium), exosome-depleted supernatant (1:1 diluted with fresh medium), or exosomes (equivalent to supernatant in fresh medium and equilibrated for comparable amounts of CD9, CD81, and CD151) were placed on top of the mesentery. Antibodies (10 Ag/mL) were added as indicated. Endothelial cell sprouting was microscopically evaluated.
In vivo angiogenesis and intravital microscopy. BDX rats received an i.p. injection of 5 Â 10 6 EGFP-transfected tumor cells and, where indicated, i.p. antibody injections (200 Ag/injection, every 3rd day; ref. 36) . At the indicated time points, rats were sacrificed, the mesentery was excised and shock-frozen for immunohistology. Alternatively, rats were anesthetized (xylazine and ketamine) and the abdomen was opened by a midline incision. Rats were fixed on a special plate automatically maintained at 37jC. The mesentery with tumors was immobilized in 50 mL of Ringer's solution at 37jC in an immersion chamber. Microscopic images were taken with a specialized microscope and a 40Â magnification objective using two fluorescence filter blocks (I3 and N2.1; Leica GmbH, Wetzlar, Germany). Images were transmitted by a video camera (Kappa GmbH, Gleichen, Germany) to a monitor (PVM-1440M, Sony, Tokyo, Japan), and recorded (sVHS, AG-7350-E, Panasonic, Osaka, Japan) for subsequent off-line analysis. Evaluation of vessel diameter and vessel density was done with special software (CapImage, Zeintl GmbH, Heidelberg, Germany). Relative vessel width was defined as the ratio between vessel area to vessel-tumor contact length. The surface of tumor blood vessels and the relative vessel width was evaluated on 20 randomly chosen fields per rat. In vivo experiments were approved by the local animal care committee (Regierungspräsidium Karlsruhe, Karlsruhe, Germany).
Statistical analysis. Significance of differences was evaluated by the Wilcoxon rank test or the two tailed Student's t test. P values were adjusted for multiple comparisons by the step-down Bonferroni method of Holm.
Results
Involvement of D6.1A in cellular morphogenesis. D6.1A-overexpressing tumor cells can induce disseminated intravascular coagulation (13) , and i.p.-injected D6.1A-overexpressing tumor cells induce hemorrhagic ascites (15) . Because the tetraspanin CD151 has been reported to be involved in cellular morphogenesis (37) with anti-CD151-inhibiting cord-like structure formation of tumor cells and fibroblasts when grown on matrigel, it became interesting to see whether D6.1A would exert similar features.
When D6.1A-overexpressing AS cells were grown on matrigel, AS-D6.1A, but not AS cells, formed cord-like, anastomosing structures. Although both lines express CD9, CD81, and CD151 at a high level, cord formation could only be inhibited by the D6.1A-specific antibody, D6.1, but not by anti-CD9, anti-CD81, or anti-CD151. AS/AS-D6.1A cells express the a3h1 and a6h1 integrins, where the latter has been described to account for anti-CD151-inhibitable cord formation of NIH3T3 cells (37) . Instead, cord formation of AS-D6.1A cells was inhibited by anti-a3 and anti-h1, but not by anti-a6 (Fig. 1A) .
Tetraspanins exert functional activities via their associating molecules, this is in line with the observed inhibition of cord formation by integrin-specific as well as tetraspanin-specific antibodies. To control for this assumption, the localization of a3, Figure 1 . Cord formation of AS-D6.1A cells on matrigel. A, AS and AS-D6.1A cells were cultured for 7 and 48 hours at 37jC on matrigel-coated 24-well plates. Only AS-D6.1A cells formed cord-like structures. To control for the effect of D6.1A on cord formation, AS-D6.1A cells were cultured for 7 hours on matrigel in the presence of D6.1, anti-CD9, anti-CD81, anti-CD151, anti-a3, anti-a6, or anti-h1 (10 Ag/mL). Phase contrast microscopy (bar, 100 Am). B, AS and AS-D6.1A cells which were cultured for 7 hours on matrigel-coated cover slides were stained with anti-h1, anti-a3, anti-a6, anti-VEGF, and secondary Cy2-labeled antibody or with Phalloidin-FITC. AS-D6.1A cells were counterstained with rhodamine-labeled D6.1. Single fluorescence and merged overlays (bar, 10 Am).
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www.aacrjournals.org a6, and h1, and colocalization with D6.1A was evaluated, respectively, in AS and AS-D6.1A cells that had been grown on matrigel for 7 hours (Fig. 1B) . D6.1A colocalized with a3 and h1, but hardly with a6. There has been no pronounced colocalization of D6.1A with actin bundles. Instead, D6.1A colocalized with VEGF.
Thus, D6.1A exhibited morphogenic features, which differed from those described for CD151 inasmuch as cord formation was inhibited by D6.1 and anti-a3, but not by anti-CD151 and anti-a6. Although these unexpected differences between the two tetraspanins are interesting and require further elucidation, we were primarily concerned as to whether the morphogenic features of D6.1A might be of functional relevance in vivo. To control the hypothesis, we first evaluated whether D6.1A-expressing tumor cells support angiogenesis in vivo.
D6.1A induces angiogenesis that is inhibited by D6.1. EGFPtransfected AS and AS-D6.1A cells were injected i.p. into syngeneic BDX rats. After 3 and 6 days, rats were anesthetized, the peritoneal cavity was opened and vessel formation was evaluated by intravital microscopy. Vessel density and vessel width were evaluated in at least 20 tumor fields per rat in different parts of the mesentery. In addition, individual fields were surveyed for up to 2 hours to see whether tumor cells would infiltrate preexisting vessels.
There was no evidence for immigration of AS or AS-D6.1A cells into preexisting vessels (data not shown). However, both tumor lines induced angiogenesis. Three days after tumor cell injection, capillary formation was seen in small AS-D6.1A tumor nodules. After 6 days, the relative vessel density was increased by more than five times in AS-D6.1A as compared with AS tumor nodules. Unlike the vessel density, the vessel width, defined by the ratio of vessel area to contact length between vessels and tumor, was only slightly increased in AS-D6.1A as compared with AS tumors. When rats received the D6.1 antibody concomitantly with the tumor cells, angiogenesis was largely abolished in both AS-D6.1A and AS tumor nodules. Anti-CD151, expressed in both tumor lines, served as a control. Vessel density was slightly reduced by anti-CD151 treatment. However, reduction in vessel density did not reach a significant level in either AS or AS-D6.1A tumors. The antiangiogenic effect of D6.1 was not a consequence of tumor growth inhibition. Neither D6.1 nor anti-CD151 inhibited tumor growth in vitro (data not shown) or in vivo ( Fig. 2A and B) .
To confirm the involvement of D6.1A in angiogenesis, AS-D6.1A cells were seeded in vitro on small pieces of the mesentery. After 72 hours of coculture, the mesentery was filled with uncountable small, branching endothelial strings. Significantly less branching endothelial cells were seen in mesenteries cocultured with AS cells. Morphogenic changes were largely absent in mesenteries cultured in the absence of tumor cells. In line with the in vitro studies on cable formation by the tumor cells and the in vivo analysis of angiogenesis induction, in vitro-induced endothelial cell branching was inhibited by D6.1 and anti-a3, but not by anti-CD9 and anti-CD151. This accounted for the strong morphogenic alterations induced by AS-D6.1A tumor cells and the weaker changes induced by AS cells. Notably, endothelial cell branching was also induced, albeit very weakly, by AS cell supernatant, but strongly by AS-D6.1A supernatant (Fig. 2C) . The latter finding might be explained by the fact that tumor cells shed D6.1A, which was recovered in tumorderived exosomes. AS and AS-D6.1A supernatant contain VEGF, which was recovered in the soluble fraction following ultracentrifugation. Instead, the tetraspanins, CD9, CD81, CD151 (AS supernatant) plus D6.1A (AS-D6.1A supernatant), are exclusively recovered in the exosome-containing pellet. Notably, although the amount of CD9, CD81, and CD151 is roughly comparable in AS and Figure 2 Continued. D, cell lysate, exosomes (100,000 Â g pellet of supernatant), cleared supernatant (10,000 Â g), and exosome-depleted supernatant (100,000 Â g) of AS and AS-D6.1A cultures were separated by SDS-PAGE and blotted with D6.1, anti-CD9, anti-CD81, anti-CD151, and anti-VEGF. Gels were loaded with 2.5 Ag of exosome preparation (corresponding to 2 mL of supernatant) and 40 AL of supernatants, Western blot of supernatant preparations being exposed to X-ray films overnight. D6.1A, CD9, CD81, CD151, and VEGF bands (arrow). The mesentery of untreated rats was cultured in the presence of AS cell-derived or AS-D6.1A cell-derived unfractionated or exosome-depleted supernatants or exosomes. AS-D6.1-derived exosomes corresponded to 2 mL of supernatant. Because AS-D6.1A supernatant-derived exosomes contained a higher amount of CD9, CD81, and CD151 than AS supernatant-derived exosomes, the relative protein content was estimated by densitometry. AS supernatant-derived exosomes added to the mesentery were adjusted to contain amounts of the tetraspanins CD9, CD81, and CD151 equivalent to that in AS-D6.1 supernatant-derived exosome preparations. To control for the D6.1A specificity of endothelial cell branching, endothelial cell-exosome cocultures contained, in addition, control IgG, D6.1, anti-CD9, or anti-CD151 (10 Ag/mL). Phase contrast microscopy is shown after 72 hours of coculture (bar, 50 Am).
AS-D6.1A lysates, fewer tetraspanins are recovered in AS-derived than in AS-D6.1A-derived exosomes. To exclude the idea that the amount of tetraspanins is decisive for functional activities, the amount of CD9, CD81, and CD151 in AS-and AS-D6.1A-derived exosome preparations was estimated by densitometry of Western blotting and exosome preparations, which were cocultured with the mesentery and adjusted to contain comparable amounts of the tetraspanins CD9, CD81, and CD151. When mesenteries were cultured with AS-derived or AS-D6.1A-derived exosomes or with exosome-depleted supernatant, branching was exclusively induced by AS-D6.1A-derived exosomes. In line with antibody-mediated inhibition of angiogenesis in vivo, exosome-induced endothelial cell branching was inhibited by D6.1, but not by anti-CD9 and anti-CD151, which instead supported endothelial cell sprouting (Fig. 2D) .
Thus, D6.1A-expressing tumor cells as well as D6.1A-containing, tumor-derived exosomes, strongly induced angiogenesis in vivo and endothelial cell branching in vitro. Surprisingly, D6.1 Figure 3 . Capillary endothelium expresses D6.1A. One week after i.p. application of AS or AS-D6.1A tumor cells, the mesentery (A) and the pancreatic gland (B ) were excised, tissue was shock-frozen and 5-Am slices were stained with (A ) anti-CD9, anti-CD81, anti-CD151, D6.1 (tetraspanins), anti-CD31 (endothelial cells), anti-a3, anti-a6, and anti-h3 (integrins) or (B ) control IgG, anti-CD31, D6.1, and anti-a3. C, shock-frozen (5-Am slices) tissue of a human pancreatic gland, of two sections from chronic pancreatitis, and of four sections from pancreatic adenocarcinoma were stained with a control IgG or anti-CD31 and anti-CO-029 (bar, 50 Am).
completely inhibited not only AS-D6.1A-induced, but also lowlevel AS-induced angiogenesis. The latter observation required further exploration.
Angiogenesis is accompanied by D6.1A expression in the capillary endothelium. We first explored how D6.1 could inhibit low-level angiogenesis induced by a D6.1A-negative tumor, and considered it likely that endothelial cells might express D6.1A because low-level D6.1A expression is seen on small capillaries, although not on larger veins and arteries (38) . When mesenteries were collected 5 days after i.p. tumor cell application, it became obvious that newly formed capillary endothelium strongly expresses D6.1A, i.e., CD31-positive cells were also stained by D6.1. In addition, the expression of a3 was up-regulated in endothelial cells and the expression of h3 integrin was augmented (Fig. 3A) . Notably, capillary D6.1A expression was independent of D6.1A expression by the tumor cell, i.e., after i.p. application of AS cells, newly formed capillaries also expressed D6.1A, but far fewer capillaries were recovered. Furthermore, AS-D6.1A-induced angiogenesis was not restricted to the tumor and the mesentery, but even in the pancreatic gland, angiogenesis was significantly augmented, as shown by CD31 staining. The pancreatic gland was apparently tumor-free. No GFP-expressing tumor cells were detected (data not shown) and only endothelial cells were stained by D6.1 (Fig. 3B) .
The finding that sprouting endothelial cells of the rat upregulated D6.1A expression prompted us to see whether this also accounts for the human homologue CO-029, high CO-029 expression being associated with poor prognosis in gastrointestinal tumors (24, 25) . Expression of CO-029 in endothelial cells of the normal pancreatic gland is hardly detectable. However, endothelial cell CO-029 expression is up-regulated in inflamed pancreatic tissue and in pancreatic cancer including the tumor stroma (Fig. 3C, third row) . Capillary CO-029 expression in the tumor tissue could be most clearly visualized in a tumor not expressing this tetraspanin (Fig. 3C, fourth row, right) .
D6.1A expression in sprouting capillary endothelium could well explain that the D6.1 antibody inhibited tumor-induced angiogenesis irrespective of whether or not the tumor cells express the D6.1A tetraspanin. On the other hand, D6.1A expression in endothelial cells may further sustain angiogenesis.
There remains the question regarding the mechanism whereby AS-D6.1A cells initiate the overshooting of angiogenesis. The findings that few i.p. seeded AS-D6.1A cells suffice for angiogenesisinduction in an adjacent, although tumor-free organ (pancreatic gland), that AS-D6.1A-derived exosomes induce endothelial cell sprouting, and that D6.1A transcription is initiated in sprouting endothelial cells, point towards the activation of cells in the tumor environment by tumor-derived D6.1A, rather than suggesting that AS-D6.1A cells themselves provide all the requirements for angiogenesis induction.
D6.1A expression in AS cells is accompanied by minor upregulation of VEGF and MMP-13. The integrin expression profile of AS and AS-D6.1A cells has already been partly described (13, 15) . AS/AS-D6.1A cells do not express a1, a2, h2, and h4 (data not shown). They express a3, a4, a5, a6, and h1, with up-regulation of a4 expression on AS-D6.1A as compared with AS cells. Both lines express the tetraspanins CD9, CD81, and CD151, CD151 expression being slightly increased in AS-D6.1A cells. The angiogenic factors VEGF, bFGF, and TNFa are expressed in both lines at low to intermediate levels, with a moderate up-regulation of VEGF expression in AS-D6.1A cells. Both lines express the antiangiogenic factors IFNg, TIMP-1, TIMP-2, and IL4 at low to intermediate levels ( Fig. 4A-C) . The two lines do not express uPA or uPAR (also evaluated by Western blotting; data not shown). AS cells express MMP-2, MMP-9, and MMP-13 at an intermediate level. MMP-13 is expressed at a higher level, and MMP-9 at a lower level, in AS-D6.1A than in AS cells. Also, MMP-9 secretion is reduced in AS-D6.1A cells (Fig. 4A and D) .
Although by no means were all proangiogenic and antiangiogenic factors evaluated, with respect to the major components, we only observed a moderate up-regulation of VEGF and MMP-13 expression in AS-D6.1A cells. Therefore, it became likely that D6.1A-expressing tumor cells may, at least in part, induce angiogenesis by transactivation. D6.1A-expressing tumor cells initiate angiogenesis-promoting activities in the tumor environment. The effect of D6.1A-expressing tumor cells on surrounding tissues was evaluated for peritoneal exudate cells and cells of the mesentery 1 week after i.p. application of AS or AS-D6.1A tumor cells. With few exceptions (a6, uPA), integrin, tetraspanin, angiogenic factor, and matrixdegrading enzyme expression was up-regulated in peritoneal macrophages from rats receiving AS or AS-D6.1A cells. Major differences between peritoneal macrophages from AS-D6.1A-bearing versus ASbearing rats were only noted for h3 and uPAR, that expression was more strongly up-regulated in peritoneal macrophages of AS-D6.1A-bearing rats (Table 1) .
More striking differences were observed between mesenteric cells collected from AS-D6.1A-bearing versus AS-bearing rats. Notably, VEGF, bFGF, MMP-2, MMP-9, uPA, uPAR, CD31, VEGFR1, and VEGFR2 expression were significantly more up-regulated in mesenteric cells of AS-D6.1A-bearing than AS-bearing rats. This was evaluated quantitatively after digestion of the mesentery by flow cytometry (Table 1 ) and zymography (data not shown) as well as semiquantitatively by immunohistochemistry (Fig. 5A) . Immunohistochemistry provided evidence that capillary endothelial cells might be the major source of VEGFR1, VEGFR2, uPA/uPAR, and MMPs.
To substantiate this assumption, a syngeneic fibroblast line and a rat aortic endothelial cell line were cultured in the presence of AS and AS-D6.1A supernatant. AS-D6.1A supernatant induced strong up-regulation of TNFa, uPA, and uPAR in the syngeneic fibroblast line. Increased VEGF, bFGF, and MMP expression were also induced by AS supernatant. Coculture of the aortic endothelial cell line with AS-D6.1A supernatant induced a selective up-regulation of CD31, VEGFR1, MMP-9, and uPAR. D6.1A and VEGFR2 expression became up-regulated, but to a lesser degree (Fig. 5B and C) . These in vitro studies with histologically defined tissue lines confirmed that D6.1A influences gene expression (particularly TNFa) in fibroblasts and (particularly D6.1A, VEGFR, and CD31) in endothelial cells.
Taken together, D6.1A is the strongest angiogenesis inducer and a D6.1A-specific antibody selectively prevents tumor angiogenesis. Tumor cell-bound and tumor cell-released D6.1A obviously initiated an angiogenic loop by inducing D6.1A expression on sprouting endothelial cells. The mode of D6.1A-induced angiogenic gene transcription in endothelial cells and adjacent fibroblasts remains to be elucidated.
Discussion
Angiogenesis is a hallmark for tumor growth and progression (2) and, accordingly, interference with the angiogenic switch is considered an important therapeutic tool (39) . Here, we reported that the tetraspanin D6.1A strongly induces angiogenesis, which is strikingly inhibited by a D6.1A-specific antibody. There is evidence that tumor cell-associated D6.1A provides only the initial trigger, with the tumor microenvironment accounting for an angiogenic amplification loop.
D6.1A-expressing tumor cells form cable-like structures on matrigel and induce pronounced angiogenesis when injected i.p. The former has also been seen in NIH3T3 cells overexpressing the tetraspanin CD151 (28), the latter has, to our knowledge, not yet been explored for other tetraspanins. Cable formation by a6h1 has been found to be due to its association with CD151, where the cytoplasmic tail is essentially required to promote outside-in signaling by a6h1 (28). CD82, instead, interferes with cable formation of a prostate tumor line, likely by down-modulating a6h1 expression. Anti-CD9, anti-CD81, and anti-CD151 did not interfere with the cable-like growth of this tumor line (40) . D6.1A-induced cable formation is inhibited by D6.1 and anti-a3, but not by anti-a6, anti-CD9, anti-CD81, and anti-CD151. Thus, the morphogenic features of tetraspanins obviously proceed differently, even if the cells have a similar tetraspanin expression profile. We do not yet know the underlying mechanisms, but we speculate that the cell type-specific integrin profile will be of importance. This assumption is derived from our observation that overexpression of a6h4 in AS-D6.1A cells inhibits cable formation and angiogenesis induction in vivo, but neither cable formation nor angiogenesis can be rescued by an anti-a6h4 antibody. 4 AS-D6.1A-promoted angiogenesis was independent of cell-cell contact, i.e., supernatant from AS-D6.1A cells sufficed for ''angiogenesis'' induction, and addition of the D6.1 antibody inhibited supernatant-induced angiogenesis. This points towards D6.1A contained in the supernatant as being the responsible element. Tetraspanins are known to be released in vesicles, called exosomes (41, 42) . Indeed, D6.1A shed by AS-D6.1A cells is exclusively recovered in exosomes, whereas VEGF is recovered in the soluble fraction. The components of AS-D6.1A-derived exosomes have not yet been fully resolved; however, we know that aside from tetraspanins, they also contain integrins. 5 Importantly, D6.1A enriched exosomes, which do not contain VEGF and induce endothelial cell branching. The enrichment of D6.1A in exosomes also provides an explanation for the observation that the D6.1 antibody inhibited AS-D6.1A supernatant-induced and exosomeinduced endothelial cell branching. D6.1A-initiated angiogenesis independent of cell-cell contact was also evidenced by strong angiogenesis in an adjacent organ, the pancreatic gland, a few days after i.p. tumor cell application. Thus, transactivation via D6.1A became a likely feature.
In fact, AS-D6.1A cells/supernatant do not provide the full requirement for angiogenesis induction, but rather stimulate adjacent cells. Peritoneal exudate cells are obviously not a major target of D6.1A, only uPA and uPAR expression became selectively up-regulated in AS-D6.1A-bearing compared with AS-bearing rats. This was different for the mesentery. The expression of several angiogenesis-related genes, such as bFGF, VEGF, MMP-2, and MMP-9 became up-regulated in the presence of AS as well as AS-D6.1A supernatant. However, the expression of some genes (CD31, D6.1A, and VEGFR) was forced by AS-D6.1A cells/supernatants. Up-regulated expression of these endothelial cell markers was confirmed in cocultures of a rat aortic endothelial cell line with AS and AS-D6.1A supernatant. In fact, up-regulated expression of D6.1A/CO-029 is a general feature of newly formed capillaries in rats and humans, which is independent of whether tumor cells express D6.1A/CO-029, albeit in the absence of tumor-derived D6.1A, only weak angiogenesis was observed. Therefore, we suggest that the D6.1A-mediated and up-regulated expression of these and additional genes is a secondary phenomenon, i.e., D6.1A does not directly promote multiple gene transcription, but initiates the 5 Unpublished finding. angiogenic switch by an as yet undefined mechanism. The finding that AS-D6.1A supernatant selectively induced changes in angiogenesis-related molecule expression was less pronounced in tissue culture lines than on the mesentery provides additional support for our interpretation and indicates the requirement for crosstalk not only between tumor cells/tumor-derived exosomes and endothelial cells, but also with the surrounding stroma. Nonetheless, strong D6.1A expression on newly formed capillaries supports the creation of an angiogenic loop.
Notably, this D6.1A-initiated angiogenic switch is hypoxiaindependent. The assumption is derived from the observations of ''angiogenesis'' induction in vitro and in vivo at a very early stage of tumor growth as well as in a tumor-free organ.
We have not yet explored the biochemical events of D6.1A-initiated angiogenesis. Because strong D6.1A expression was noted in sprouting endothelial cells and because D6.1 inhibited angiogenesis, even if the tumor cells did not express D6.1A, we suggest that D6.1A expression on endothelial cells is an early event in tumor-derived D6.1A-initiated angiogenesis, where D6.1A-expressing endothelial cells subsequently support the maintenance of angiogenesis. Tetraspanins, including D6.1A, are located in glycolipid-enriched membrane microdomains (37) , which serve as a scaffold for signal-transducing molecules (10, (16) (17) (18) . Some tetraspanins associate with G protein-coupled receptors (GPCR) and mediate signal transduction via associated heterotrimeric G proteins (43) . Although a GPCR association is not yet known for D6.1A, D6.1A associates with prostaglandin F2a receptor regulatory protein (14) , which regulates the binding of ligands to GPCRs (44) . D6.1A also associates with PKC and a type II phosphoinositide-4-kinase, which initiates signal transduction via PIP2 phosphorylation (14) . Finally, tetraspanins could induce the activation of associated integrins (10, 16, 18) . D6.1A associates with a3 (13, 14) , which, similar to a4 expression, becomes strongly upregulated in endothelial cells during D6.1A-initiated angiogenesis. Both a3 and a4 have been implicated in MMP transcription (45, 46) . Thus, there are several pathways whereby D6.1A can contribute to transcription/activation of angiogenesis-promoting molecules.
There remains the question regarding the primary interaction of D6.1A with endothelial cells. We hypothesize that such an interaction is mediated either by cell membrane D6.1A-associated molecules and/or by molecules enriched in D6.1A-containing exosomes. Tetraspanin-mediated protein sorting as described for the immunologic and the so-called infectious synapse (10, 11, 17, 47) could well facilitate such a mechanism of transactivation. Alternatively, one could speculate that D6.1A-containing microdomains or exosomes may be fusogenic, a feature well known, e.g., CD9, that is essential for egg-sperm and myoblast fusion (48, 49) . We will explore these hypotheses by analyzing the content of AS-D6.1A-derived compared with AS-derived exosomes and by evaluating the mode of exosome-mediated intercellular communication.
Conclusions
The tumor growth-promoting activity of the tetraspanin, D6.1A/ CO-029, is due to its capacity to induce the angiogenic switch. Notably, membrane-bound as well as exosomal D6.1A supports angiogenic factor transcription in targeted cells. As newly formed capillaries also strongly express D6.1A, an angiogenic loop is created that further sustains capillary formation. Supporting the central role of the tetraspanin, the process can be inhibited by a D6.1A-specific antibody. Thus, antibody blockade of this tetraspanin could well become a new and supposedly highly selective and efficient drug.
